Targeting the spliceosome through RBM39 degradation results in exceptional responses in high-risk neuroblastoma models

Aberrant alternative pre-mRNA splicing plays a critical role in MYC-driven cancers and therefore may represent a therapeutic vulnerability. Here, we show that neuroblastoma, a MYC-driven cancer characterized by splicing dysregulation and spliceosomal dependency, requires the splicing factor RBM39 fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Shivendra, Quarni, Waise, Goralski, Maria, Wan, Shibiao, Jin, Hongjian, Van de Velde, Lee-Ann, Fang, Jie, Wu, Qiong, Abu-Zaid, Ahmed, Wang, Tingting, Singh, Ravi, Craft, David, Fan, Yiping, Confer, Thomas, Johnson, Melissa, Akers, Walter J., Wang, Ruoning, Murray, Peter J., Thomas, Paul G., Nijhawan, Deepak, Davidoff, Andrew M., Yang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598007/
https://www.ncbi.nlm.nih.gov/pubmed/34788094
http://dx.doi.org/10.1126/sciadv.abj5405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598007/
https://www.ncbi.nlm.nih.gov/pubmed/34788094
http://dx.doi.org/10.1126/sciadv.abj5405

Ejemplares similares